Research Insights

Unlocking the Mystery of Cardiovascular Risk: New Insights on Lp(a) and hs-CRP

Have you ever wondered about the hidden factors behind cardiovascular risk? A recent study published in JAMA Cardiology 2024 has uncovered intriguing connections between lipoprotein(a) (Lp[a]) and high-sensitivity C-reactive protein (hs-CRP), shedding light on how these biomarkers influence heart health. We have previously covered what Lp[a] is, and its impact on cardiovascular health. This can be found by clicking here.

The Study

Researchers delved into data from three diverse cohorts spanning general populations and clinical trials. Their goal? To unravel the relationship between Lp(a) and cardiovascular risk, regardless of inflammation levels indicated by hs-CRP. The link to the paper can be found here.

Study Findings

The findings were significant. Across the board, higher levels of Lp(a) were associated with increased cardiovascular risk, irrespective of hs-CRP levels. This held true whether participants were in the primary prevention phase, without prior cardiovascular disease, or in the secondary prevention phase, with existing cardiometabolic conditions.


Why It Matters

This research challenges previous notions that inflammation might be the key factor driving cardiovascular risk associated with elevated Lp(a) levels. Instead, it suggests that Lp(a) exerts its influence independently, adding a new layer of complexity to our understanding of heart health.



For individuals concerned about their cardiovascular risk, these findings offer valuable insights. Assessing Lp(a) levels could provide crucial information beyond traditional risk factors like cholesterol and blood pressure. Understanding your Lp(a) status could empower you and your healthcare provider to take proactive steps in managing your heart health.


What’s Next

As we delve deeper into the intricacies of cardiovascular risk, further research will be needed to explore the potential therapeutic implications of these findings. Could targeting Lp(a) levels be a game-changer in cardiovascular prevention and treatment? Only time and continued scientific inquiry will tell.


Final Thoughts

In the dynamic landscape of cardiovascular research, every discovery brings us one step closer to unraveling the mysteries of heart disease. The study’s revelations about Lp(a) and hs-CRP serve as a reminder of the intricate interplay between biological markers and cardiovascular outcomes. By staying informed and proactive about our heart health, we can work towards a future where cardiovascular disease is managed and prevented altogether.

In conclusion, this study invites us to rethink our approach to cardiovascular risk assessment and management, offering new avenues for exploration and potential interventions that could make a real difference in the lives of millions worldwide.

Explore all things Lp(a) with Cardiologist Dr Arul Baradi in our article here.

Search articles


Subscribe for exclusive heart health resources, valuable tips, and the latest research updates.

Editor's Picks

Empowering heart health

Subscribe to our newsletter and be the first to receive valuable insights, tips, and resources on heart health.

other anti-anginals

When first-line therapies for angina, such as beta blockers, calcium channel blockers, and nitrates, prove inadequate or are not well-tolerated, second-line therapies may be considered.
Perhexiline is a unique medication that enhances the heart's ability to utilize fatty acids for energy, reducing its reliance on oxygen and lowering oxygen demand. This action helps improve blood flow and alleviates chest pain in some patients with refractory angina.
Nicorandil is another second-line option with a dual mechanism of action. It opens potassium channels in smooth muscle cells, causing vasodilation and enhancing coronary blood flow. Additionally, nicorandil also stimulates nitric oxide release, further dilating blood vessels and reducing heart workload.
Trimetazidine is an anti-ischemic agent that improves cardiac efficiency by enhancing glucose metabolism and shifting the heart's energy production to a more oxygen-efficient process. As second-line therapies, these medications offer alternative approaches for managing angina in individuals who do not respond adequately to first-line treatments or those experiencing side effects from other medications.

lipid lowering therapies

Lipid-lowering therapies play a critical role in managing coronary artery disease (CAD), a condition characterized by the narrowing of blood vessels that supply the heart. Among the most commonly discussed and debated classes of medications are statins, which effectively reduce cholesterol levels and are widely prescribed to lower the risk of cardiovascular events. Alongside statins, other medications like ezetimibe, fibrates, and niacin are also utilized to target specific aspects of lipid metabolism, such as cholesterol absorption, triglyceride levels, and raising high-density lipoprotein (HDL) cholesterol. Additionally, the introduction of medications that inhibit PCSK9, an enzyme involved in cholesterol metabolism, has provided a promising new approach to further lower LDL cholesterol levels. These PCSK9 inhibitors, such as Repatha (evolocumab), have shown significant efficacy in reducing LDL cholesterol levels in patients with CAD, especially for those who may not respond well to traditional therapies.


Nitrates are widely used to treat angina and provide quick relief for chest pain. Commonly available in the form of sublingual sprays or tablets, patches, and long-acting tablets, nitrates work by dilating blood vessels, allowing for increased blood flow and reduced resistance. This dilation eases the heart's workload, leading to a decreased demand for oxygen and prompt alleviation of angina symptoms. Sublingual nitrates act rapidly and are often used to provide immediate relief during angina attacks, while patches and long-acting tablets are employed for preventive purposes. However, nitrates may cause side effects such as headaches, dizziness, and flushing, which usually subside over time.

calcium channel blockers

Calcium channel blockers, including amlodipine, felodipine, cardizem (diltiazem), and verapamil, are commonly prescribed for the treatment of angina. These medications work by inhibiting the influx of calcium into the muscle cells of the heart and blood vessels, leading to their relaxation. As a result, blood vessels widen, promoting improved blood flow and reduced blood pressure. In the context of angina, this relaxation decreases the heart's workload, lowering the demand for oxygen and alleviating chest pain. Calcium channel blockers offer a valuable treatment option for individuals with angina, but it is essential to be aware of potential side effects, which may include headaches, dizziness, flushing, and ankle swelling.

Beta blockers

Beta blockers, such as metoprolol, propranolol, atenolol, carvedilol, and bisoprolol, play a crucial role in treating angina. By blocking certain receptors in the heart, they effectively reduce heart rate and the force of contraction, thereby easing the heart's workload. This mechanism of action leads to a decreased demand for oxygen, making beta blockers highly effective in relieving chest pain associated with angina. As with any medication, it's important to consider potential side effects, including tiredness, worsened asthma, erectile dysfunction in some males, and more vivid dreams during sleep. Consult your healthcare provider to determine the suitability of beta blockers for managing your angina and overall heart health.

Anti-platelet Medications

Anti-platelet medications play a crucial role in preventing blood clot formation, reducing the risk of serious cardiovascular events such as heart attacks and strokes. Among the widely used anti-platelet drugs are aspirin, clopidogrel, and ticagrelor.

Aspirin: This well-known medication inhibits platelet activation, making it less likely for platelets to stick together and form clots. Aspirin is commonly used for primary and secondary prevention of heart attacks and strokes.

Clopidogrel: As a potent anti-platelet agent, clopidogrel works by blocking specific receptors on platelets, preventing them from aggregating. It is often prescribed to patients with acute coronary syndrome, those undergoing stent procedures, and for some cases of peripheral arterial disease.

Ticagrelor: Ticagrelor is another effective anti-platelet drug that works by inhibiting platelet activation. It is used in acute coronary syndrome, often given alongside aspirin to reduce the risk of heart-related events.